• 07/15/2014

    « The success of our IPO makes me believe that our product is promising »

    Interview of CROSSJECT’s CEO, Patrick Alexandre, about his inspiration behind CROSSJECT’s unique technology, the company’s milestones, the product benefits of Zeneo and the motivation for an IPO.  Performing exceptionally well since its IPO in February and a fund-raising of €17 million CROSSJECT attracts more and more the attention of investors and consumers. 

    Read more
  • CROSSJECT launches bioequivalence clinical study with ZENEO® Methrotrexate

    With the announcement of the recruitment process of patients for its clinical study which represents an indispensable condition for the deposition of its marketing authorization; CROSSJECT has reached an important step in its commercialization plans for Zeneo® Methotrexate in Europe, which is envisaged for the end of 2015. ZENEO® Methotrexate offers new perspectives in the treatment of rheumatoid arthritis. The bioequivalence study aims at proving that its needle-free injection system is as efficient as the conventional injection by classical syringe.

    Read more


  • 06/02/2014

    Crossject will be present at BIO San Diego 2014

    Meet us in San Diego, June 23th to 26th, during the 2014 BIO international convention. Contact Tim Muller:  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 05/15/2014

    Crossject will be present at Drug Delivery Partnership Europe

    Meet us in Hamburg, September 17th and 18th to Drug Delivery Partnership Europe.
    Contact Tim Muller:  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos